Hideyuki Yamamoto

Hideyuki Yamamoto

Auto-generated profile, based on publicly available information

Hideyuki Yamamoto

Department of Biochemistry, Graduate School of Medicine University of the Ryukyus Okinawa Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2012 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
YKYutaka Kondo
Yutaka Kondo
SHSayomi Higa-Nakamine
Sayomi Higa-Nakamine
NNNobuhiro Noguchi
Nobuhiro Noguchi
NMNoriko Maeda
Noriko Maeda
STSeikichi Toku
Seikichi Toku
HYHideyuki Yamamoto
Hideyuki Yamamoto
Toll-like receptor 5 (TLR5) recognizes bacterial flagellin and activates host inflammatory responses, mainly through activation of the NF-κB pathway. Although pulmonary fibrosis occurs in some cases of lung infection by flagellated bacteria, the pathological roles of TLR5 stimulation in pulmonary fibrosis have yet to be elucidated. In the present study, we first confirmed that flagellin activated the NF-κB pathway in cultured A549 alveolar epithelial cells. Next, we examined the types of genes whose expression was modulated by flagellin in the cells. Microarray analysis of gene expression indicated that flagellin induced a change in gene expression that had a similar trend to transforming growth factor-β1 (TGF-β1), a key factor in the induction of epithelial-mesenchymal transition (EMT). Biochemical analysis revealed that TGF-β1and flagellin increased the level of fibronectin protein, while they reduced the level of E-cadherin protein after 30 h of treatment. Interestingly, simultaneous treatment with TGF-β1and flagellin significantly augmented these EMT-related changes. Flagellin strongly activated p38 MAP kinase, and the activation was sustained for longer than 30 h. SB203580, an inhibitor of p38 MAP kinase, inhibited the upregulation of fibronectin by both flagellin and TGF-β1. Simultaneous treatment with TGF-β1and flagellin augmented the activation of p38 MAP kinase by TGF-β1or flagellin alone. These results strongly suggest that flagellin cooperates with TGF-β1in the induction of EMT in alveolar epithelial cells.

1 August 2014 in Journal Of Hypertension
Verified
Journal Article
Closed access
STShinji Takai
Shinji Takai
DJDenan Jin
Denan Jin
HCHong Chen
Hong Chen
WLWen Li
Wen Li
HYHideyuki Yamamoto
Hideyuki Yamamoto
HOHaruki Okamura
Haruki Okamura
To clarify the role of chymase in hypertension, we evaluated the effect of a chymase inhibitor, TY-51469, on vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats (SHR-SP). SHR-SP were treated with TY-51469 (1 mg/kg per day) or placebo from 4 to 12 weeks old or until death. Wistar-Kyoto rats were used as a normal group. SBP was significantly higher in both the placebo and TY-51469 groups than in the normal group, but there was no significant difference between the two treatment groups. Plasma renin, angiotensin-converting enzyme activity and angiotensin II levels were not different between the placebo and TY-51469 groups. In contrast, vascular chymase-like activity was significantly higher in the placebo than in the normal group, but it was reduced by TY-51469. Acetylcholine-induced vascular relaxation was significantly higher in the TY-51469 group than in the placebo group. There was significant augmentation of the number of monocytes/macrophages and matrix metalloproteinase-9 activity in aortic tissue from the placebo group compared with the normal group, and these changes were attenuated by TY-51469. There were also significant increases in mRNA levels of monocyte chemoattractant protein-1 and tumor necrosis factor-α in the placebo group that were attenuated by TY-51469. Cumulative survival was significantly prolonged in the TY-51469 group compared with the placebo group. Chymase might play an important role in vascular dysfunction via augmentation both of matrix metalloproteinase-9 activity and monocyte/macrophage accumulation in SHR-SP, and its inhibition may be useful for preventing vascular remodeling and prolonging survival.

1 July 2010 in Allergy and Asthma Proceedings
Verified
Journal Article
Closed access
HYHideyuki Yamamoto
Hideyuki Yamamoto
TYTakechiyo Yamada
Takechiyo Yamada
SKSeita Kubo
Seita Kubo
YOYoko Osawa
Yoko Osawa
YKYuichi Kimura
Yuichi Kimura
SFShigeharu Fujieda
Shigeharu Fujieda
Adequate treatment is critical for maintaining a good level of quality of life (QOL) during the pollen season in patients suffering from seasonal allergic rhinitis (SAR). Olopatadine, a histamine H1-receptor antagonist, has been approved in the United States and Europe for the treatment of AR and allergic conjunctivitis as a nasal spray and an ophthalmic solution, respectively. We conducted a randomized, double-blind, placebo-controlled study to determine whether orally administered olopatadine for prophylactic purposes might also be effective for the control of nasal allergy symptoms, especially nasal congestion, in patients with SAR due to Japanese cedar pollen (SAR-JP). A total of 110 patients with SAR caused by JP were randomized to the treatment. The subjects recorded their nasal and ocular allergic symptom scores in a diary, and their QOL was assessed by the Japanese version of the Rhinoconjunctivity Quality of Life Questionnaire. Treatment with oral olopatadine significantly suppressed sneezing (p < 0.001), rhinorrhea (p < 0.001), and nasal congestion (p < 0.05). The total QOL score during the peak JP season was superior in the olopatadine group than in the placebo group (p < 0.05). However, orally administered olopatadine did not exert any significant effect against eye itching and watering of the eyes, unlike olopatadine nasal spray. Treatment with olopatadine tablets yielded superior QOL scores in the domains of usual daily activities and outdoor activities when compared with placebo. No serious adverse effects of the treatment were reported during the study period. These results suggest that oral olopatadine treatment may be a useful alternative treatment strategy for AR.

1 June 2000 in Clinical Immunology
Verified
Journal Article
Closed access
SFShigeharu Fujieda
Shigeharu Fujieda
SSSatoru Suzukib
Satoru Suzukib
HSHiroshi Sunagaa
Hiroshi Sunagaa
HYHideyuki Yamamotoa
Hideyuki Yamamotoa
MSMizue Sekia
Mizue Sekia
HSHitoshi Saito
Hitoshi Saito

17 October 1994 in FEBS Letters
Verified
Journal Article
Open access
PDF file
TMTomoyuki Miyashita
Tomoyuki Miyashita
HYHideyuki Yamamoto
Hideyuki Yamamoto
YNYoshitake Nishimune
Yoshitake Nishimune
MNMasami Nozaki
Masami Nozaki
TMTakashi Morita
Takashi Morita
AMAizo Matsushiro
Aizo Matsushiro
Treatment of cultured cells with sodium butyrate, that is the histone deacetylase inhibitor, induces the histone hyperacetylation and the expressions of various mammalian genes without affecting the level of protein synthesis. However, butyrate is a non‐specific inhibitor of deacetylase because of its effects on various other enzymes and nuclear proteins other than histones. On the other hand, Trichostatin A (TSA) was recently found to be a potent and specific inhibitor of histone deacetylase. We examined the effect of TSA on the expression of mouse cytokeratin A (endo A). TSA increased endo A expression in F9 cells, and was efffective at a much lower concentration than sodium butyrate. We also examined the changes of chromatin structure induced by the two drugs by a DNase I‐hypersensitivity assay. Both drugs induced the formation of a DNase I‐hypersensitive site (DH site) in only the promoter region. The precise mechanism(s) by which the two drugs increase endo A gene expression is unknown, but these results suggest that endo A expression is induced by inhibition of histone deacetylase and that the effect is at the transcriptional level.

1 January 2014 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
HYHideyuki Yamamoto
Hideyuki Yamamoto
SHSayomi Higa-Nakamine
Sayomi Higa-Nakamine
NNNobuhiro Noguchi
Nobuhiro Noguchi
NMNoriko Maeda
Noriko Maeda
YKYutaka Kondo
Yutaka Kondo
KSKazuhiro Sugahara
Kazuhiro Sugahara
Four transmembrane tyrosine kinases constitute the ErbB protein family: epidermal growth factor receptor (EGFR) or ErbB1, ErbB2, ErbB3, and ErbB4. In general, the structure and mechanism of the activation of these members are similar. However, significant differences in homologous desensitization are known between EGFR and ErbB4. Desensitization of ligand-occupied EGFR occurs by endocytosis, while that of ErbB4 occurs by selective cleavage at the cell surface. Because ErbB4 is abundantly expressed in neurons from fetal to adult brains, elucidation of the desensitization mechanism is important to understand neuronal development and synaptic functions. Recently, it has become clear that heterologous desensitization of EGFR and ErbB4 are induced by endocytosis and cleavage, respectively, similar to homologous desensitization. It has been reported that heterologous desensitization of EGFR is induced by serine phosphorylation of EGFR via the p38 mitogen-activated protein kinase (p38 MAP kinase) pathway in various cell lines, including alveolar epithelial cells. In contrast, the protein kinase C pathway is involved in ErbB4 cleavage. In this review, we will describe recent advances in the desensitization mechanisms of EGFR and ErbB4, mainly in alveolar epithelial cells and hypothalamic neurons, respectively.